Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX versus ANSAID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX versus ANSAID.
ANAPROX vs ANSAID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
250-500 mg orally twice daily; maximum 1.5 g/day; for extended-release: 375-750 mg orally twice daily
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
None Documented
None Documented
Terminal elimination half-life 12-17 hours; prolonged in elderly (up to 20 hours) and in renal impairment.
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
Renal excretion of metabolites (95%) and unchanged drug (<5%); biliary/fecal elimination minor (<5%).
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
Category C
Category C
NSAID
NSAID